Abbreviations used in clinical trials: Difference between revisions
No edit summary |
No edit summary |
||
| Line 68: | Line 68: | ||
EU European Union | EU European Union | ||
FBG Fasting blood glucose | FBG Fasting blood glucose | ||
| Line 74: | Line 73: | ||
FDA United States Food and Drug Administration | FDA United States Food and Drug Administration | ||
FSH Follicle-stimulating hormone | |||
GCP Good Clinical Practice | GCP Good Clinical Practice | ||
| Line 104: | Line 103: | ||
HTG Hypertriglyceridemia | HTG Hypertriglyceridemia | ||
ICF Informed consent form | |||
ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use | ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use | ||
IFCC International Federation of Clinical Chemistry | IFCC International Federation of Clinical Chemistry | ||
IMP Investigational medicinal product | IMP Investigational medicinal product | ||
IQR Interquartile range | IQR Interquartile range | ||
IRB Institutional Review Board | IRB Institutional Review Board | ||
ITT Intent-to-Treat | ITT Intent-to-Treat | ||
IWRS Interactive Web Response System | IWRS Interactive Web Response System | ||
JAS Japanese Atherosclerosis Society | JAS Japanese Atherosclerosis Society | ||
LBBB Left bundle branch block | |||
LDL-C Low-density lipoprotein cholesterol | LDL-C Low-density lipoprotein cholesterol | ||
LOE Lack of efficacy | LOE Lack of efficacy | ||
LpPLA2 Lipoprotein-associated phospholipase A2 LVH Left ventricle hypertrophy | |||
LpPLA2 Lipoprotein-associated phospholipase A2 | |||
LVH Left ventricle hypertrophy | |||
MACE Major adverse coronary event | MACE Major adverse coronary event | ||
MI Myocardial infarction | MI Myocardial infarction or mitral insufficiency | ||
mITT Modified Intent-to-Treat | mITT Modified Intent-to-Treat | ||
NCEP National Cholesterol Education Program | NCEP National Cholesterol Education Program | ||
NGSP National Glycohemoglobin Standardization Program NMR Nuclear magnetic resonance | |||
NSTE-ACS Non-ST-segment elevation acute coronary syndrome O3FA Omega-3 fatty acid | NGSP National Glycohemoglobin Standardization Program | ||
ODIS Off drug in | |||
NMR Nuclear magnetic resonance | |||
NSTE-ACS Non-ST-segment elevation acute coronary syndrome | |||
O3FA Omega-3 fatty acid | |||
ODIS Off drug in stud | |||
y | |||
OGTT Oral glucose tolerance test | OGTT Oral glucose tolerance test | ||
OR Odds ratio | OR Odds ratio | ||
PAD Peripheral arterial disease | PAD Peripheral arterial disease | ||
PCI Percutaneous coronary intervention PCSK9 Proprotein convertase subtilisin kexin 9 PH Proportional hazard | |||
PCI Percutaneous coronary intervention | |||
PCSK9 Proprotein convertase subtilisin kexin 9 | |||
PH Proportional hazard | |||
PI Principal Investigator | PI Principal Investigator | ||
PP Per protocol | PP Per protocol | ||
PVD Peripheral vascular disease | |||
RBC Red blood cells | RBC Red blood cells | ||
RLP-C Remnant lipoprotein cholesterol | |||
RR Relative risk | RR Relative risk | ||
SAE Serious adverse event | SAE Serious adverse event | ||
SAP Statistical Analysis Plan | SAP Statistical Analysis Plan | ||
SC Steering Committee | SC Steering Committee | ||
SPC Summary of Product Characteristics | SPC Summary of Product Characteristics | ||
SUSAR Suspected unexpected serious adverse reaction | |||
SUSAR Suspected unexpected serious adverse reaction | |||
TC Total cholesterol | TC Total cholesterol | ||
TEAE Treatment-emergent adverse event | TEAE Treatment-emergent adverse event | ||
TG Triglycerides | TG Triglycerides | ||
TIA Transient Ischemic Attack | TIA Transient Ischemic Attack | ||
TIMI Thrombolysis In Myocardial Infarction | TIMI Thrombolysis In Myocardial Infarction | ||
ULN Upper limit of normal | ULN Upper limit of normal | ||
US United States | US United States | ||
USPI United States Prescribing Information | USPI United States Prescribing Information | ||
VLDL-C Very low density lipoprotein cholesterol | VLDL-C Very low density lipoprotein cholesterol | ||
WBC White cell blood count | WBC White cell blood count | ||
Revision as of 19:03, 24 October 2019
ABI Ankle-brachial index
ACC American College of Cardiology
ACS Acute coronary syndrome
AE Adverse event
AHA American Heart Association
AIDS Acquired immune deficiency syndrome
ALT Alanine aminotransferase
AP Angina pectoris
apo B Apolipoprotein B
APOC3 Apolipoprotein C3
AST Aspartate aminotransferase
ATP Adult Treatment Panel
BMI Body mass index
BUN Blood urea nitrogen
CABG Coronary artery bypass graft
CAD Coronary artery disease
CBC Complete blood count
CEC Clinical Endpoint Committee
CHD Coronary heart disease
CHF Congestive heart failure
CI Confidence interval
CK-MB Creatine kinase-MB fraction
CrCL Creatinine clearance
CRF Case report form
CV Cardiovascular
CVD Cardiovascular disease
DHA Docosahexaenoic acid
DMC Data Monitoring Committee
EC Independent Ethics Committee
ECG Electrocardiogram
EDC Electronic data capture
eGRF Estimated glomerular filtration rate
EPA Eicosapentaenoic acid
Ethyl-EPA ethyl eicosapentaenoic acid
EU European Union
FBG Fasting blood glucose
FDA United States Food and Drug Administration
FSH Follicle-stimulating hormone
GCP Good Clinical Practice
GGT Gamma-glutamyl transferase
GMP Good Manufacturing Practice
GWAS Genome-wide association study
HbA1c Hemoglobin A1c
Hct Hematocrit
HDL-C High-density lipoprotein cholesterol
HF Heart failure
Hgb Hemoglobin
HIV Human immunodeficiency virus
HR Hazard ratio
hs-CRP High-sensitivity C-reactive protein
hsTnT High-sensitivity troponin T
HTG Hypertriglyceridemia
ICF Informed consent form
ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
IFCC International Federation of Clinical Chemistry
IMP Investigational medicinal product
IQR Interquartile range
IRB Institutional Review Board
ITT Intent-to-Treat
IWRS Interactive Web Response System
JAS Japanese Atherosclerosis Society
LBBB Left bundle branch block
LDL-C Low-density lipoprotein cholesterol
LOE Lack of efficacy
LpPLA2 Lipoprotein-associated phospholipase A2
LVH Left ventricle hypertrophy
MACE Major adverse coronary event
MI Myocardial infarction or mitral insufficiency
mITT Modified Intent-to-Treat
NCEP National Cholesterol Education Program
NGSP National Glycohemoglobin Standardization Program
NMR Nuclear magnetic resonance
NSTE-ACS Non-ST-segment elevation acute coronary syndrome
O3FA Omega-3 fatty acid
ODIS Off drug in stud y OGTT Oral glucose tolerance test
OR Odds ratio
PAD Peripheral arterial disease
PCI Percutaneous coronary intervention
PCSK9 Proprotein convertase subtilisin kexin 9
PH Proportional hazard
PI Principal Investigator
PP Per protocol
PVD Peripheral vascular disease
RBC Red blood cells
RLP-C Remnant lipoprotein cholesterol
RR Relative risk
SAE Serious adverse event
SAP Statistical Analysis Plan
SC Steering Committee
SPC Summary of Product Characteristics
SUSAR Suspected unexpected serious adverse reaction
TC Total cholesterol
TEAE Treatment-emergent adverse event
TG Triglycerides
TIA Transient Ischemic Attack
TIMI Thrombolysis In Myocardial Infarction
ULN Upper limit of normal
US United States
USPI United States Prescribing Information
VLDL-C Very low density lipoprotein cholesterol
WBC White cell blood count